Compare Quest Diagnostics Inc (DGX) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Herbalife Nutrition Ltd — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B). The key difference: Quest Diagnostics Inc is far larger — about 19× Herbalife Nutrition Ltd's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Herbalife Nutrition Ltd for 43 Days on average.
| DGX | HLF | |
|---|---|---|
Market Cap | $25.48B | $1.34B |
Volume | 941,866 | 1,589,457 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $19.96 |
52-Week Low | $173.49 | $7.75 |
Typical Hold Time | 56 Days | 43 Days |
Enterprise Value | $31.23B | $3.18B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Herbalife (HLF) trades at $12.86, up 1.62% on the day, with a bullish technical signal and a consensus analyst price target of $19.00 implying significant upside. The company reported Q2 2026 EPS of $0.51, missing expectations, but reaffirmed full-year 2026 guidance. Financials show a net income margin of 3.16% for 2025, with a low P/E of 8.22 and P/S of 0.26, suggesting potential undervaluation. Recent news includes a $250 million share repurchase authorization and a planned CEO transition effective October 31, 2026.
The outlook for HLF is cautiously optimistic, with valuation metrics and analyst sentiment supporting a bullish case, but risks include recent earnings misses, high debt levels, and ongoing leadership changes. The stock presents a value opportunity if the company can execute on its growth and margin expansion plans while managing its leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
